Infrequent Screening but High Prevalence of Antinuclear Antibodies in Patients with Neuropsychiatric Disorders

Jihad Ben Gabr¹ and Andras Perl ¹, ¹SUNY Upstate Medical University, Syracuse, NY

Meeting: ACR/ARP Annual Meeting 2019

Keywords: ANA, neuropsychiatric disorders and SLE

Session Information

Date: Sunday, November 10, 2019

Title: Measures Of Healthcare Quality Poster I: Testing, Screening, & Treating

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: The American College of Rheumatology (ACR) established case definitions of 19 specific neuropsychiatric syndromes seen in patients with systemic lupus erythematosus (SLE) (1). Therefore, we evaluated the frequency of antinuclear antibody (ANA) screening by immune that has the greatest sensitivity to detect SLE (2).

Methods: This quality improvement project examined the electronic medical records (EMR) of patients diagnosed with 17 neuropsychiatric conditions documented at our institution between 2013 until 2019 (Table 1). Patients with existing SLE have been excluded. ANA testing was done by indirect immunofluorescence using HEp-2 cells as antigen (2). Significant ANA titer was defined as titer >1:50. Our findings were compared to published studies in similar patient populations which were available in PubMed for 8/17 conditions. Statistical analysis was performed with chi-square test using GraphPad version 5.0 software.

Results: Table 1 outlines the findings in a total number of 178,585 patients with 17 neuropsychiatric diagnosis in our cohort. ANA was assessed in 19,369 subjects (10.7%). Rates of testing ranged between 6.7% (seizure) and 23.8% (Guillain-Barre syndrome, GBS). Surprisingly, ANA testing was done in 8.9% of patients with psychosis. Each population was evaluated for the numbers of patients who were screened and found to have elevated ANA. Compared to peer-reviewed literature our cohort was larger in number with greater prevalence of positive ANA with the exception of myasthenia gravis, which unveiled similar levels of prevalence.

Conclusion: Up to 80% of SLE manifest a neuropsychiatric disorder, which may benefit from treatment targeting the immune system and inflammation. The prevalence ANA testing was surprisingly low in patients with neuropsychiatric disorders. However, among the tested patients, the prevalence of ANA exceeded those in the literature in 7/8 conditions, which likely reflects a preference for testing in cases where disease manifestations occurred outside the nervous system. Further studies are clearly warranted to substantiate the role of systemic inflammatory diseases, such as SLE, in neuropsychiatric disorders.

TABLE

Table 1: Prevalence of ANA testing in patients with 17 neuropsychiatric conditions. Total Dx, total population at SUNY Upstate. ANA testing done = Total number of each population at Upstate screened for ANA. ANA+, patients with positive ANA not including SLE patients. %ANA+, percent of positive ANA screened from total population not including SLE patients. Total dx -lit-= Total diagnosis found in the literature screened for ANA. ANA+, number of positive ANA found within the population from the outside literature; %ANA+, percent positive ANA found within the literature; X2 p, chi square values comparing prevalence of ANA between our cohorts and ones in the published literature. Ref.= references that can be seen under reference section.

Disclosure: J. Ben Gabr, None; A. Perl, None.

To cite this abstract in AMA style:

Ben Gabr J, Perl A. Infrequent Screening but High Prevalence of Antinuclear Antibodies in Patients with Neuropsychiatric Disorders [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/infrequent-screening-but-high-prevalence-of-antinuclear-antibodies-in-patients-with-neuropsychiatric-disorders/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/infrequent-screening-but-high-prevalence-of-antinuclear-antibodies-in-patients-with-neuropsychiatric-disorders/